What is William Blair’s Forecast for AXSM FY2026 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at William Blair raised their FY2026 earnings per share (EPS) estimates for Axsome Therapeutics in a research report issued to clients and investors on Friday, October 10th. William Blair analyst M. Minter now forecasts that the company will earn $1.46 per share for the year, up from their prior estimate of $1.33. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share.

A number of other brokerages also recently commented on AXSM. Morgan Stanley began coverage on Axsome Therapeutics in a report on Thursday, July 3rd. They set an “overweight” rating and a $190.00 target price for the company. Royal Bank Of Canada upped their target price on Axsome Therapeutics from $184.00 to $189.00 and gave the company an “outperform” rating in a report on Tuesday, August 5th. Wells Fargo & Company upgraded Axsome Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday, October 8th. Finally, B. Riley initiated coverage on Axsome Therapeutics in a report on Wednesday, October 1st. They set a “buy” rating and a $179.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $177.93.

Axsome Therapeutics Price Performance

Shares of Axsome Therapeutics stock opened at $123.52 on Monday. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The company has a market cap of $6.16 billion, a PE ratio of -24.36 and a beta of 0.52. The business has a 50 day moving average of $117.53 and a 200 day moving average of $109.96. Axsome Therapeutics has a 52 week low of $75.56 and a 52 week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.08. The firm had revenue of $150.04 million during the quarter, compared to analyst estimates of $140.02 million. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.

Hedge Funds Weigh In On Axsome Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AXSM. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Axsome Therapeutics by 5.2% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 20,644 shares of the company’s stock valued at $2,408,000 after acquiring an additional 1,017 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Axsome Therapeutics by 8.6% during the first quarter. Janney Montgomery Scott LLC now owns 14,923 shares of the company’s stock valued at $1,740,000 after acquiring an additional 1,178 shares in the last quarter. Prosperity Wealth Management Inc. bought a new position in shares of Axsome Therapeutics during the first quarter valued at $321,000. Lisanti Capital Growth LLC bought a new position in shares of Axsome Therapeutics during the first quarter valued at $3,881,000. Finally, DAVENPORT & Co LLC bought a new position in shares of Axsome Therapeutics during the first quarter valued at $218,000. 81.49% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Herriot Tabuteau sold 27,907 shares of the firm’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $118.96, for a total transaction of $3,319,816.72. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at $859,961.84. This trade represents a 79.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roger Jeffs sold 20,000 shares of the firm’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $121.60, for a total value of $2,432,000.00. Following the transaction, the director owned 90,974 shares of the company’s stock, valued at $11,062,438.40. The trade was a 18.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 243,332 shares of company stock worth $28,824,746. 22.40% of the stock is owned by corporate insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.